

Special Issue

Latest Development in Multiple Myeloma

Message from the Guest Editor

Multiple myeloma is an incurable B-cell malignancy frequently accompanied by many complications, like osteolytic lesions and renal failures. In the age of novel anti-myeloma drugs, including proteasome inhibitors and immunomodulatory drugs, the response rate and survival duration have been improved. In addition, immunotherapy using therapeutic antibodies and CAR-T cells has led to a great advance in the treatment of relapse/refractory patients. This Special Issue will discuss recent developments in our understanding of the biology and genomic characteristics, detection of minimal residual disease, innovations in the field of multiple myeloma.

Guest Editor

Dr. Yoichi Imai

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Deadline for manuscript submissions

closed (15 October 2019)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/26142

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)